American Association for Cancer Research

Skip to Main Content

Table 1

Odds ratios of colorectal cancer for quintiles of serum IGF-I, and of three different measures of IGFBP-3^a

	Quintiles									P for trend
		1	2	3	4	5				P for trend
IGF-I	1.00	1.49 (0.63–3.52)	1.30 (0.56–3.02)	1.52 (0.67–3.47)	1.88 (0.72–4.91)	0.25
IGFBP-3
IRMA-Immunotech	1.00	1.70 (0.78–3.70)	1.15 (0.50–2.66)	0.92 (0.40–2.12)	2.46 (1.09–5.57)	0.19

ELISA-DSL	1.00	0.89 (0.41–1.94)	0.69 (0.30–1.57)	1.23 (0.55–2.76)	1.24 (0.54–2.86)	0.49

IGF-I adjusted for IGFBP-3; IGFBP-3 measured by
IRMA-Immunotech	1.00	1.59 (0.73–3.47)	0.56 (0.23–1.39)	1.43 (0.61–3.36)	1.23 (0.47–3.22)	0.70

ELISA-DSL	1.00	1.48 (0.65–3.35)	1.07 (0.47–2.43)	1.23 (0.52–2.95)	1.03 (0.39–2.69)	0.93

	Quintiles									P for trend
		1	2	3	4	5				P for trend
IGF-I	1.00	1.49 (0.63–3.52)	1.30 (0.56–3.02)	1.52 (0.67–3.47)	1.88 (0.72–4.91)	0.25
IGFBP-3
IRMA-Immunotech	1.00	1.70 (0.78–3.70)	1.15 (0.50–2.66)	0.92 (0.40–2.12)	2.46 (1.09–5.57)	0.19

ELISA-DSL	1.00	0.89 (0.41–1.94)	0.69 (0.30–1.57)	1.23 (0.55–2.76)	1.24 (0.54–2.86)	0.49

IGF-I adjusted for IGFBP-3; IGFBP-3 measured by
IRMA-Immunotech	1.00	1.59 (0.73–3.47)	0.56 (0.23–1.39)	1.43 (0.61–3.36)	1.23 (0.47–3.22)	0.70

ELISA-DSL	1.00	1.48 (0.65–3.35)	1.07 (0.47–2.43)	1.23 (0.52–2.95)	1.03 (0.39–2.69)	0.93

^a

Study based on 102 cases of colorectal cancer and 200 matched controls; see Kaaks et al., (3) for details.